Plain-English translation of NCT07094048 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Multiple myeloma patients receiving a BCMA-directed T cell engager often have low levels of infection-fighting proteins in their blood, which increases their risk of serious infections. This study is testing whether patients need the same high level of immunoglobulin supplementation (the medication) or whether a lower level works just as well. The goal is to help doctors give the right amount of this treatment to prevent infections without giving more than necessary.
While doctors know that giving extra immunoglobulin helps prevent infections in these patients, they don't know the ideal target level to aim for. This medication works better for some patients at higher levels than others, and finding the right balance could improve care and reduce unnecessary treatment.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to one of three groups: one receiving higher-dose immunoglobulin infusions (either through an IV or under the skin), one receiving lower-dose infusions, or one that starts without the medication but can switch to either dose if needed. You'll receive these infusions regularly as part of your cancer care, and the study team will monitor your infection rates and immunoglobulin levels over approximately three months to see which approach works best.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Canada